Search results for "far"

showing 10 items of 6421 documents

0135 : New regulators of iron metabolism, hepcidin and erythroferrone, in acute myocardial infarction

2016

Background Dysfunctional iron storage and transport are common in patients with chronic heart failure and associated with poor prognosis. Body iron could contribute to the pathogenesis of coronary artery disease (CAD) through its ability to induce oxidative stress. However, studies on the relationship between iron metabolism and CAD have yielded conflicting results. Patients and methods from the obseRvatoire des Infarctus de Cote d’Or (RICO) survey, 31 consecutive patients admitted in Intensive Care Unit for a first AMI were included. Serum concentrations of iron, transferrin, ferritin, the iron-regulatory hormone hepcidin and erythroferrone (a new hepcidinregulating hormone), transferrin s…

medicine.medical_specialty030204 cardiovascular system & hematologyHematocrit03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHepcidinTotal iron-binding capacityInternal medicineerythroferroneMedicine030212 general & internal medicineMyocardial infarctionComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationbiologymedicine.diagnostic_testbusiness.industryTransferrin saturationErythroferrone[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthFerritinEndocrinologychemistryTransferrinbiology.proteinhepcidinbusinessCardiology and Cardiovascular Medicine
researchProduct

0127: Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction

2016

Background Atrial fibrillation (AF), whether silent or symptomatic, is a frequent and severe complication of acute myocardial infarction (AMI). Asymmetric dimethylarginine (ADMA), an endogenous eNOS inhibitor, is a risk factor for endothelial dysfunction. We addressed the relationship between ADMA plasma levels and AF occurrence in AMI. Methods 273 patients hospitalized for AMI were included. Continuous electrocardiographic monitoring (CEM) ≥48 hours was recorded and ADMA was measured by High Performance Liquid Chromatography on admission blood sample. Results The incidence of silent and symptomatic AF was 39(14%) and 29 (11%), respectively. AF patients were markedly older than patients wit…

medicine.medical_specialty030204 cardiovascular system & hematologyPathogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHeart rateMedicine030212 general & internal medicineMyocardial infarctionRisk factorEndothelial dysfunctionComputingMilieux_MISCELLANEOUSEjection fractionbusiness.industryAtrial fibrillationEndothelial function[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseAtrial fibrillation3. Good healthMyocardial infarctionchemistryCardiologyCardiology and Cardiovascular MedicinebusinessAsymmetric dimethylarginine
researchProduct

Providing pediatric well-care and sick visits in the COVID-19 pandemic era: the recommendations of the Italian pediatric society.

2020

AbstractPediatricians have observed a significant decrease in in-person child health visits during the COVID-19 pandemic. In the post lockdown period, the coronavirus trend remains positive in Italy but fears of a second wave have recently grown in Italy due to active hotbeds of contagion. The pandemic may negatively affect the care of pediatric patients and overall children welfare as it may present with severe signs and symptoms or it may complicate. The Italian Pediatric Society recommend to separate well visits from sick ones, to educate families and to promote hygienic strategies to provide an adequate pediatric assistance in case of a second pandemic wave.

medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)COVID19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)media_common.quotation_subjectPneumonia ViralChild WelfareSigns and symptomsPediatricsChild healthBetacoronavirusPandemicmedicineDisease Transmission InfectiousHumansVisitChildChildrenPandemicsSocieties Medicalmedia_commonMaternal and child healthbusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsSettore MED/38ItalyFamily medicinePractice Guidelines as TopicCommentarybusinessCoronavirus InfectionsWelfareItalian journal of pediatrics
researchProduct

Characteristics of patients from the Polish Registry of Acute Coronary Syndromes during the COVID-19 pandemic: the first report

2021

medicine.medical_specialty2019-20 coronavirus outbreakInfection ControlCoronavirus disease 2019 (COVID-19)business.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19Retrospective cohort studyMiddle AgedPandemicEmergency medicinemedicineInfection controlHumansST Elevation Myocardial InfarctionPolandRegistriesAcute Coronary SyndromeCardiology and Cardiovascular MedicinebusinessNon-ST Elevated Myocardial InfarctionPandemicsAgedRetrospective StudiesKardiologia Polska
researchProduct

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct

Clinical Cases on Colorectal Cancer Emergency

2019

You have to manage in the emergency room a 75-year-old man with a medical history of pulmonary embolism 4 months ago and currently treated with warfarin. He has no history of abdominal surgery. He consults for diffuse abdominal pain, cessation of flatus and stools for 4 days, and fever of 38.7 °C and chills for 24 h. He vomited once 24 h ago. He also experienced asthenia and recent weight loss of 7 kg over the past 6 months not attributable to diet or exercise. He complains of progressively aggravating alternation of diarrhea and constipation for 3 months. He finally remembers that he noticed several times in the last months the presence of red blood in the stools, about which he did not wo…

medicine.medical_specialtyAbdominal painclinical caseConstipationbusiness.industryWarfarinmedicine.diseaseColorectal cancer emergencyPulmonary embolismSurgerySettore MED/18 - Chirurgia GeneraleHemorrhoidsmedicineMedical historyChillsmedicine.symptombusinessAbdominal surgerymedicine.drug
researchProduct

Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease

2006

Abstract Background Sphingomyelin (SM) is the major phospholipid in cell membranes and in lipoproteins. In human plasma, SM is mainly found in atherogenic lipoproteins; thus, high levels of SM may promote atherogenesis. Methods We investigated in a median follow up of 6.0 years the association of SM with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) in stable and unstable patients, and its relation to other marker of atherosclerosis in 1,102 patients with angiographically documented CAD and 444 healthy controls. Results and discussion Logistic regression analysis showed that SM categorized by median was associated with an elevated risk for CAD (HR 3.2…

medicine.medical_specialtyAcute coronary syndromeApolipoprotein BEndocrinology Diabetes and MetabolismMedicine (miscellaneous)lcsh:TX341-641Clinical nutritionGastroenterologyCoronary artery diseasechemistry.chemical_compoundMedian follow-upInternal medicinemedicineMyocardial infarctionRisk factorlcsh:RC620-627Nutrition and DieteticsTriglyceridebiologybusiness.industryResearchmedicine.diseaselcsh:Nutritional diseases. Deficiency diseasesEndocrinologychemistrybiology.proteinbusinesslcsh:Nutrition. Foods and food supplyNutrition & Metabolism
researchProduct

Prise en charge au long cours par les anti-agrégants plaquettaires oraux après un syndrome coronaire aigu

2007

Cardiovascular disease is the primary cause of early death and morbidity in the industrialized world and is becoming a growing problem in many developing countries. Coagulation inhibitors play a major role in the management of the acute phase of ACS whether in association with reperfusion strategies or not. Currently, and in accordance with the results of major randomised studies, for medium and long-term management, the association of Clopidogrel and aspirin is the treatment of choice. However, despite the recognised benefits of this therapeutic strategy and above all the recommendations of learned societies, which have placed this bi-therapy in class I, according to national and internati…

medicine.medical_specialtyAcute coronary syndromeAspirinbusiness.industryDeveloping countryEarly deathDiseasemedicine.diseaseClopidogrelSurgeryMedicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessIntensive care medicineTherapeutic strategymedicine.drugAnnales de Cardiologie et d'Angéiologie
researchProduct

State of the Art-High-Sensitivity Troponins in Acute Coronary Syndromes.

2020

In cases of suspected acute coronary syndrome (ACS), rapid and accurate diagnosis is essential to establish effective evidence-based medical treatment. Patients' history, clinical examination, 12-lead electrocardiogram, and cardiac biomarkers are cornerstones in initial management. Since high-sensitivity cardiac troponins were established, they have markedly expedited and revolutionized rule-in and rule-out pathways of patients with ACS and changed our everyday clinical practice. Thus, they have become an indispensable tool in daily routine in emergency units. This review focuses on historical and contemporary standards in laboratory biomarkers of myocardial injury and discusses their impli…

medicine.medical_specialtyAcute coronary syndromeCardiac biomarkersMyocardial InfarctionPhysical examinationContext (language use)030204 cardiovascular system & hematologySensitivity and SpecificityDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeIntensive care medicinebiologymedicine.diagnostic_testMedical treatmentbusiness.industryGeneral Medicinemedicine.diseaseTroponinTroponinbiology.proteinBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessBiomarkersCardiology clinics
researchProduct

“Ultra-sensitive” cardiac troponins: Requirements for effective implementation in clinical practice

2018

The measurement of cardiac troponins, either cardiac troponin I or T, has become the culprit of clinical decision making in patients with suspected acute coronary syndrome (ACS), especially in those with non-ST elevation myocardial infarction (NSTEMI). The leading analytical mainstays of cardiac troponin immunoassays include the limit of blank (LoB), limit of detection (LoD), functional sensitivity, the 99th percentile of a healthy reference population, along with the percentage of “ostensibly healthy” subjects displaying measurable values 50% in the general healthy population. The very recent commercialization of methods with further improved analytical sensitivity (i.e., “ultra-sensitive”…

medicine.medical_specialtyAcute coronary syndromeCardiac troponinClinical BiochemistryClinical Chemistry TestsReview030204 cardiovascular system & hematologyCulpritacute coronary syndromecardiac troponin; myocardial infarction; acute coronary syndrome; diagnostics03 medical and health sciences0302 clinical medicineTroponin TLimit of DetectionInternal medicinecardiac troponinmedicinediagnosticsHumansIn patient030212 general & internal medicineMyocardial infarctionUltra sensitiveacute coronary syndrome; cardiac troponin; diagnostics; myocardial infarctionbusiness.industryHealthy populationBiochemistry (medical)Troponin Imedicine.diseaseClinical Practicemyocardial infarctionCardiologybusinessAlgorithmsBiochemia Medica
researchProduct